New targeted cancer drug tested in patients who ran out of options
NCT ID NCT05980416
Summary
This early-stage study tested a new targeted cancer drug called EO-3021 in adults with advanced stomach and other digestive cancers that had stopped responding to standard treatments. The main goal was to find a safe dose and see if the drug caused tumors to shrink. The study was terminated early and did not move to later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health/Wake Forest University
Charlotte, North Carolina, 28204, United States
-
City of Hope
Duarte, California, 91010, United States
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Henry Ford Cancer
Detroit, Michigan, 48202, United States
-
Johns Hopkins University - Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
Seoul, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
UW Carbone Cancer Center - Cancer Connect
Madison, Wisconsin, 53792, United States
-
Yale - Smilow Cancer Hospital
New Haven, Connecticut, 06519, United States
-
Yonsei University
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.